Myopia control for children in Malaysia: what works

Key takeaways

Nothing reverses a child's short-sightedness. Myopia control means slowing how fast it climbs, so the final prescription and the lifetime risk end lower.
Four treatments have trial evidence for slowing it: low-dose atropine drops, myopia-control spectacle lenses, myopia-control soft contact lenses, and overnight rigid lenses. Red-light therapy is newer and less certain. All are prescribed and monitored; none is a product to shop for.
Atropine strengths are a fraction of the full-strength drop: 0.01, 0.025 and 0.05 percent. Stronger slows more with slightly more side effects; the strength is the doctor's choice with you, not a brand choice.
How sure is the evidence? The 2025 Cochrane review rates most of the effect sizes as low or very low certainty, so treat each number as a direction, not a promise. Malaysian prevalence figures from two 2026 reviews vary widely with how children were measured.
Time outdoors has good evidence for delaying the start of myopia and weak evidence for slowing it once it has begun. Blue-light glasses, eye exercises and supplements have no trial evidence for slowing it.
In Malaysia the public route runs through a referral to a government hospital eye clinic; the private route is booked directly. Ask for a written estimate before any treatment starts, and ask the questions in the checklist article.

The conversation usually starts at the optical shop. Your child's "power" has gone up again, someone has mentioned special lenses or drops, and you have come home with a leaflet and no way of telling how much of it is evidence. This page is the map I would draw for you across the desk. It covers what has been shown in trials to slow short-sightedness, what has not, when it is worth starting, and how the public and private routes work in Malaysia.

It does not recommend products, because the treatments are types, not brands, and because which one suits your child is a decision for the appointment, not for a page. Where I give an effect size, I also say how sure the evidence is, because the largest review of the trials, from Cochrane in 2025, rates much of it as low or very low certainty.

Two words before we start. Short-sightedness, myopia, is the eye growing slightly too long for its own focusing power, so distance blurs while near stays sharp. "Progression" is that growth continuing year on year through childhood, the yearly climb in the prescription. Everything below is about slowing that climb. Nothing below reverses it.

How common is short-sightedness in Malaysian children?

Common enough to be worth watching for, and the exact figure depends on who was counted and how. Two systematic reviews of Malaysian studies, both published in 2026, do not give the same answer.

One pooled 14 studies of 13,367 children and adolescents and found about 17 percent overall: roughly 2.5 percent at ages 0 to 6, 26 percent at 7 to 12 and 43 percent at 13 to 18. The other pooled 17 studies of 19,281 children and found 25 percent before adjustment and about 16 percent after it, with about 1 percent in preschool and 30 percent in primary school.

Both reviews warn that the studies disagree with each other a great deal: they measured short-sightedness in different ways, some without the drops that relax the focusing muscle, which tends to overcall it, and the first review notes that none of the studies it pooled covered the whole country.

Read the numbers as "few preschoolers, and a quarter or more of children by the end of primary school", not as a precise rate. The pattern that matters is the climb with age, which is why the age at which short-sightedness settles is worth knowing.

What is myopia control, and what can it honestly do?

It is a small group of treatments that slow how fast a child's short-sightedness worsens. It cannot undo what is already there: once the eye has grown long enough to blur the distance, it does not shrink back, and a promise to reverse or cure a child's myopia is one no treatment has been shown to keep.

The honest goal is a lower final prescription than the child would otherwise have reached, and a lower lifetime risk of the eye problems that come with a very long eye. That is a smaller promise than "fixing" it, and a real one. I have written about why so many children are short-sighted now; this page is the next step, for the family that has been told the number is climbing. The treatments side by side are in slowing myopia down: drops, lenses and honest numbers.

Why does slowing it matter, if glasses fix the blur anyway?

Because glasses correct the blur but not the length of the eye, and the length carries the long-term risk: a very short-sighted eye is a stretched eye, more prone to trouble later in life.

The clinical statement of the American Academy of Ophthalmology puts numbers on it: compared with an eye that is not short-sighted, a prescription between about minus one and minus three carries roughly four times the risk of a retinal detachment, and beyond minus three roughly ten times.

High myopia is also linked with glaucoma, cataract and a form of damage to the central retina called myopic maculopathy, and what changes once the number gets high is its own article. None of that is a reason to panic about a child in minus two glasses. It is the reason a doctor takes a fast-climbing prescription seriously rather than simply writing a stronger one each year.

Does time outdoors slow it down?

It has good evidence for delaying the start of short-sightedness, and weaker evidence for slowing it once it has begun. That distinction is the single most useful thing on this page, and it is often blurred in advertising.

In the research pooled by the Academy's task force, each extra hour a child spent outdoors per week was linked with about two percent lower odds of becoming short-sighted, and the practical target eye doctors quote is roughly one to two hours outside a day. The children this protects most are the ones who are not short-sighted yet but are at risk, which I cover in pre-myopia.

For a child who is already myopic, most studies have not found that outdoor time slows the climb. So: get the younger siblings outside, because it may spare them the problem, and keep the short-sighted child outside too, because it is good for a great deal else and it costs nothing, but do not rely on it alone to hold the prescription. Screen breaks help comfort; they are not shown to slow progression.

What are low-dose atropine drops, and what do 0.01 and 0.025 percent mean?

They are a class of prescription eye drops, a drop in each eye at bedtime, used for years, that slow the growth of the eye; they have the most trial evidence of the treatments on this page, though, as below, much of it is rated low certainty. Atropine is an old medicine; at full strength, one percent, it is the long-acting drop used to widen the pupil for some examinations.

Myopia control uses a fraction of that. The number on the bottle is grams of atropine in every hundred millilitres, so 0.01 percent is one hundredth of the full-strength drop, and even the strongest of the three studied, 0.05 percent, is a twentieth of it. The largest trial comparing those three strengths followed 438 children aged four to twelve for a year.

The placebo group's prescription moved by about 0.81 dioptres. On 0.01 percent it moved by about 0.59, on 0.025 percent by about 0.46, and on 0.05 percent by about 0.27. The eye grew least on the strongest drop, and pupil size and near focusing were affected a little more as the strength rose. Vision and day-to-day quality of life were not affected at any of the three.

That is one good trial. The Cochrane review pooled 104 trials in 17,509 children, most of them in Asia, in which untreated children progressed by a median of about 0.65 dioptres in a year. It found low-dose atropine, below 0.1 percent, slowed that by about a quarter of a dioptre over a year, but rates the certainty as very low, which means the true effect could be quite different.

Medium doses slowed it by about half a dioptre at low certainty, and high doses (0.5 percent or more) by about nine tenths at moderate certainty, with more side effects. It found limited evidence on progression after treatment stops. For where large trials disagreed, see atropine drops for myopia: what the numbers say.

What that means for your child is a choice of strength, not of brand, made by the doctor with you. A stronger drop slows more and is a little more likely to cause light sensitivity or near blur; a weaker one is gentler and slows less, and older trials found less "rebound", the catch-up that can follow stopping.

The drops are used every night for two to three years or more, with regular reviews of the prescription and, where the clinic measures it, the length of the eye. Side effects at these strengths are usually mild: some redness or itchiness around the eye, some light sensitivity, a slightly larger pupil, occasionally near blur.

These are prescription drops, monitored by a doctor, not something to source yourself, and stopping them is a decision for a review, not for home.

What are myopia-control spectacle lenses?

Ordinary-looking glasses whose lens does two jobs at once: the centre corrects distance the way any lens does, and the surrounding zone is built to blur the edge of vision slightly, a signal that appears to slow the eye's growth. These are sold under several brand names, and the lens designs differ, so think of them as a type rather than a product.

Trials of this design suggest a modest slowing, and the best results came with the glasses worn full time during waking hours; a lens that lives in the school bag does nothing. The certainty is not high: in the Cochrane review, lenses of this kind (peripheral-plus or defocus designs) slowed progression by about 0.45 dioptres over a year, rated very low certainty.

In the United States a design of this kind is approved for children aged six to twelve. Older bifocal and progressive lenses, the kind adults wear for reading, slowed progression by so little in trials that the researchers concluded it did not justify a change in practice; the Cochrane review puts their effect at about 0.14 dioptres over a year, at low certainty.

If your child is at the age of a first pair, what happens after a child is prescribed glasses covers the getting-used-to-them part; the myopia-control question is a separate one to raise at the review.

What about contact lenses: overnight lenses and myopia-control soft lenses?

Two different lenses, one shared caveat. Overnight hard contact lenses, orthokeratology or ortho-k, are worn while the child sleeps and gently flatten the front of the eye so that they see clearly without glasses by day, and in trials they also slow the eye's growth. Soft myopia-control lenses are worn by day and work on the same edge-of-vision principle as the spectacle lenses above; the evidence for them sits in school-age children, roughly six to twelve, and they do not work for every child.

For the soft lenses the Cochrane review found about a quarter of a dioptre of slowing over a year, at very low certainty. For overnight lenses it measured the length of the eye rather than the prescription, and found about 0.18 millimetres less growth over a year at moderate certainty, the firmest of the lens results; adding low-dose atropine to them probably slowed the eye's growth a little further.

The shared caveat is infection. Any contact lens carries a risk of infection of the cornea, the clear front window of the eye, and overnight wear carries a considerably higher risk than daytime wear, of an infection that can scar the cornea and, at worst, cost sight.

That is why these options need a child old enough to handle a lens cleanly, a family able to keep to the routine, and more follow-up visits than the other options. For the right family they are a good choice. They are not a shortcut.

What about red-light therapy?

It is a newer option, and it needs more care than the ones above. In the Cochrane review it showed one of the larger slowings at one year, about 0.8 dioptres, but its certainty is rated very low, and the review notes that adverse events were not consistently reported across trials. Devices differ, and the review gives no reliable picture of what years of use do to the eye.

What is known, and the questions worth asking about the device and retina scans, are in red-light therapy for myopia: what Malaysian parents should know. If a child ever says a spot in the middle of their vision is blurred or missing after a session, stop and see an eye doctor within days.

What does not slow short-sightedness?

Anything not on the list above, because the list of treatments with trial evidence is short. Blue-light glasses are the commonest: there is no scientific evidence that the light from screens damages children's eyes, and blue-light lenses are not a myopia-control treatment. Eye exercises, vision-training programmes and supplements do not appear on that list, and I know of no trial showing that any of them slows the growth of the eye.

Wearing weaker glasses than prescribed, or none at all, is sometimes suggested as a way to "rest" the eye; it is not a treatment either, and it leaves a child seeing badly. Nor do glasses weaken a child's eyes, a myth covered in children's eye myths. As for screens, what closeness does and does not mean is in why children sit so close to the screen, and the evidence tying near work to short-sightedness is inconsistent. Limit screens for the reasons that hold anyway, comfort and sleep.

When should myopia control start, and who decides?

Once a child is confirmed short-sighted by a proper measurement, and especially once the prescription is seen to be climbing, with the strongest reason to act in the youngest children. A child who becomes short-sighted at six has far more growing years ahead than one who becomes short-sighted at twelve, so the same yearly climb ends somewhere very different. That is why the trials start early: the atropine study above enrolled children from four.

The measurement matters as much as the age. A child's true prescription is measured with drops that relax the focusing muscle, because children can over-focus and hide the real number, and a shop reading taken without those drops can overstate the short-sightedness (what each number on the slip means).

From there, the decision is a conversation with an eye doctor who sees children about how fast it is moving, how old the child is, and what the family's routine makes realistic. Progress is then followed by repeating that measurement, and where the clinic can, measuring the length of the eye, at regular reviews; how fast is too fast sets out what a typical yearly change looks like at each age.

Public or private: what are the routes in Malaysia, and what do the rules say about cost?

The public route runs through a klinik kesihatan or GP, who refers your child to the eye clinic of a Ministry of Health hospital. Bring the referral letter and any previous prescriptions.

The private route is an eye clinic that sees children, booked directly.

Charges differ from clinic to clinic and change over time, and the drops, the lenses and the extra tests are usually charged separately, so I do not quote figures here. Ask any clinic for a written estimate before you start, and ask what the follow-up visits will cost. Ten questions to ask before you pay for myopia control is a checklist you can take with you.

Optometrists share this work: they measure and dispense spectacles and contact lenses, including the myopia-control designs, while prescribing the drops and examining the health of the eye is the doctor's part.

One local fact worth knowing, because it tells you this is being studied seriously here rather than imported on trust.

A randomised trial called ATOM-MY, registered on the public ClinicalTrials.gov registry as NCT07329777, is recruiting children aged five to ten at two university hospitals in the Klang Valley to compare 0.025 percent atropine drops with placebo for the first year, after which the placebo group is also given the drops, with a two-year follow-up and its first results not due before 2027. The registry still lists it as recruiting, with no results; it is a study, not a service.

See an eye doctor sooner if…

Your child's prescription is climbing quickly between checks, or your child became short-sighted young, in the early primary-school years or before.
Your child squints, sits ever closer, rubs their eyes, or complains of headaches or blur despite up-to-date glasses.
A short-sighted child sees sudden flashes, a shower of new floaters, or a shadow or curtain across their vision: that is a same-day emergency, not a review.
You have been offered a treatment that promises to reverse or cure short-sightedness. Nothing does, and it is worth a proper opinion before you pay.

Common questions

Can my child's short-sightedness be reversed?

No. Once the eye has grown long enough to blur the distance, that length does not shrink back, and no treatment has been shown to undo it. What can be done is to slow the yearly climb, which is a real and useful goal: a lower final prescription and a lower lifetime risk of retinal problems. Be wary of anyone who promises more than that.

Which atropine strength is best: 0.01, 0.025 or 0.05 percent?

There is no single best strength, which is why the choice is made at the appointment rather than by a page. In the trial that compared all three over a year, the stronger drop slowed the climb more and affected pupil size and near focusing a little more; the weaker drop was gentler, slowed less, and in earlier studies produced less rebound when stopped. Age, how fast the prescription is moving, and how your child copes with light sensitivity all feed into the choice. Be aware that the Cochrane 2025 review rates the evidence for low-dose atropine as very low certainty, so these differences are best read as a guide, not a guarantee.

Are low-dose atropine drops safe to use for years?

At these strengths the side effects reported in trials have been mild: some redness or itchiness around the eye, some light sensitivity, a slightly larger pupil, occasionally near blur, and in the year-long comparison of three strengths neither vision nor day-to-day quality of life was affected. They are prescription drops used every night for two to three years or longer, with regular reviews. Do not stop them abruptly on your own, because progression can catch up after stopping; make that decision at a review.

How sure are we that these treatments work?

Less sure than the headlines suggest. The 2025 Cochrane review pooled 104 trials in 17,509 children and found that several treatments may slow short-sightedness over a year, but it rates the certainty as very low for low-dose atropine, defocus spectacle lenses, soft myopia-control lenses and red-light therapy, low for multifocal spectacles and medium-dose atropine, and moderate only for high-dose atropine (0.5 percent or more) and overnight lenses (on eye length). Most of the trials were in Asia, and few followed children after stopping. Very low certainty does not mean a treatment does nothing; it means the true effect could be quite different from the number. That is why the plan is set with a doctor and checked by measurement.

Can I just get myopia-control lenses at the optical shop without seeing a doctor?

The spectacle and soft contact lenses are dispensed by optometrists, so in practice many families start there. What I would ask is that the decision rests on a proper measurement first: a child's true prescription is measured with drops that relax the focusing muscle, and a shop reading taken without them can mislead. Whether your child needs myopia control at all, and whether drops, lenses or both suit them, is a conversation for an eye doctor who sees children, and the two professions work best together.

Is orthokeratology (overnight lenses) safe for a child?

It slows the eye's growth in trials, and it lets a child see clearly by day without glasses, but overnight lens wear carries a considerably higher risk of infection of the clear front of the eye than daytime wear, and that infection can scar and, at worst, cost sight. So it suits a child old enough to handle a lens cleanly, a family who can keep to the routine, and a clinic that will see you often. It is a good option for the right family, and it is not a shortcut.

Do blue-light glasses help slow short-sightedness?

No. There is no scientific evidence that the light from screens damages children's eyes, and blue-light lenses are not a myopia-control treatment. If your child needs glasses, the money is better spent on the right prescription, worn full time. The same goes for eye exercises and supplements: none has trial evidence for slowing the growth of the eye.

Is low-dose atropine being studied in Malaysian children?

Yes. A randomised trial called ATOM-MY, registered on ClinicalTrials.gov as NCT07329777, is recruiting children aged five to ten at two university hospitals in the Klang Valley. It compares 0.025 percent atropine drops with placebo for the first year, where neither the family nor the examiner knows who is on the real drop; in the second year the placebo group is also given the drops, so follow-up runs two years. It began in September 2025 and its first results are not due before 2027, so it has nothing to report yet. I mention it because it means low-dose atropine is being studied here, in Malaysian children, rather than only imported on trust.

How do I find out what myopia control will cost in Malaysia?

I do not quote figures, because they differ from clinic to clinic and change over time. What I can tell you is how to find out. In the public route a klinik kesihatan or GP refers your child to a government hospital eye clinic; in the private route you book an eye clinic directly. Either way, the drops, lenses and follow-up tests are usually charged separately, so ask for a written estimate before you start, and ask what the follow-up visits will cost.

How will I know if the treatment is working?

By the rate of change, not by the blur going away. Your doctor repeats the prescription measurement with focusing-relaxing drops, and where the clinic can, measures the length of the eye, and compares the climb with what it was before. A prescription that still rises a little on treatment is not a failure; the aim is a slower climb than untreated, and it takes time, usually a year of measurements, to judge that fairly.

Does my child still need outdoor time if they are on drops or special lenses?

Yes, but be clear about why. Outdoor time has good evidence for delaying the start of short-sightedness, so it matters most for the younger siblings who are not yet myopic. For a child already short-sighted, the evidence that it slows the climb is weak, so it is not a substitute for treatment. It remains free, good for sleep and mood, and part of any sensible plan; it is simply not the part doing the slowing.

browse by worry Short-sightedness (myopia) →

References

American Academy of Ophthalmology · Myopia control in children · www.aao.org
American Academy of Ophthalmology · Reducing the global burden of myopia by delaying onset and slowing progression (Task Force on Myopia clinical statement, 2021) · www.aao.org
Yam JC et al. · Low-Concentration Atropine for Myopia Progression (LAMP) Study, Ophthalmology 2019 (0.05%, 0.025% and 0.01% atropine versus placebo) · pubmed.ncbi.nlm.nih.gov
American Academy of Ophthalmology EyeWiki · Myopia (treatment evidence and rebound after stopping atropine) · eyewiki.aao.org
American Academy of Ophthalmology · Preventing childhood myopia with sunshine and outdoor time · www.aao.org
American Academy of Ophthalmology · Screen use for kids (no evidence that screen light damages eyes) · www.aao.org
AAPOS · Glasses for children (glasses do not weaken a child's eyes) · aapos.org
ClinicalTrials.gov · NCT07329777, Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY) · clinicaltrials.gov
Lawrenson JG et al. · Interventions for myopia control in children: a living systematic review and network meta-analysis, Cochrane Database of Systematic Reviews 2025 · pubmed.ncbi.nlm.nih.gov
Tan ESY, Agarwal P, Teng CL · Prevalence of myopia in children and adolescents: a systematic review of Malaysian prevalence studies, Malaysian Journal of Medical Sciences 2026 · pmc.ncbi.nlm.nih.gov
Sui CF et al. · Myopia prevalence in Malaysian children: a systematic review and meta-analysis, Frontiers in Public Health 2026 · www.frontiersin.org

By Dr Chan Li Yen. General information only. It does not replace a consultation. If you are worried about your child's eyes or vision, please see an eye doctor.

Myopia control in Malaysia: what slows a child's short-sightedness, what does not, and when to start